[1]
|
Salari, N., Morddarvanjoghi, F., Abdolmaleki, A., Rasoulpoor, S., Khaleghi, A.A., Hezarkhani, L.A., et al. (2023) The Global Prevalence of Myocardial Infarction: A Systematic Review and Meta-Analysis. BMC Cardiovascular Disorders, 23, Article No. 206. https://doi.org/10.1186/s12872-023-03231-w
|
[2]
|
Khan, M.A., Hashim, M.J., Mustafa, H., Baniyas, M.Y., Al Suwaidi, S.K.B.M., AlKatheeri, R., et al. (2020) Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus, 12, e9349. https://doi.org/10.7759/cureus.9349
|
[3]
|
Zhao, M., Li, N. and Zhou, H. (2023) SGLT1: A Potential Drug Target for Cardiovascular Disease. Drug Design, Development and Therapy, 17, 2011-2023. https://doi.org/10.2147/dddt.s418321
|
[4]
|
Silber, S., Albertsson, P., Avilés, F.F., Camici, P.G., Colombo, A., Hamm, C., et al. (2005) Guidelines for Percutaneous Coronary Interventions. European Heart Journal, 26, 804-847. https://doi.org/10.1093/eurheartj/ehi138
|
[5]
|
Jernberg, T., Hasvold, P., Henriksson, M., Hjelm, H., Thuresson, M. and Janzon, M. (2015) Cardiovascular Risk in Post-Myocardial Infarction Patients: Nationwide Real World Data Demonstrate the Importance of a Long-Term Perspective. European Heart Journal, 36, 1163-1170. https://doi.org/10.1093/eurheartj/ehu505
|
[6]
|
沈璞杰, 张晓艳. SGLT-2抑制剂治疗糖尿病肾病的研究进展[J]. 承德医学院学报, 2024, 41(3): 239-244.
|
[7]
|
Arnott, C., Li, Q., Kang, A., Neuen, B.L., Bompoint, S., Lam, C.S.P., et al. (2020) Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 9, e014908. https://doi.org/10.1161/jaha.119.014908
|
[8]
|
Roy, R., Vinjamuri, S., Baskara Salian, R., Hafeez, N., Meenashi Sundaram, D., Patel, T., et al. (2023) Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review. Cureus, 15, e42113. https://doi.org/10.7759/cureus.42113
|
[9]
|
(2023) Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 147, e674. https://doi.org/10.1161/CIR.0000000000001142
|
[10]
|
McMurray, J.J.V., Docherty, K.F. and Jhund, P.S. (2020) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine, 382, 972-973. https://doi.org/10.1056/NEJMc1917241
|
[11]
|
He, G., Yang, G., Huang, X., Luo, D., Tang, C. and Zhang, Z. (2023) SGLT2 Inhibitors for Prevention of Primary and Secondary Cardiovascular Outcomes: A Meta-Analysis of Randomized Controlled Trials. Heart & Lung, 59, 109-116. https://doi.org/10.1016/j.hrtlng.2023.02.009
|
[12]
|
Lahnwong, C., Palee, S., Apaijai, N., Sriwichaiin, S., Kerdphoo, S., Jaiwongkam, T., et al. (2020) Acute Dapagliflozin Administration Exerts Cardioprotective Effects in Rats with Cardiac Ischemia/reperfusion Injury. Cardiovascular Diabetology, 19, Article No. 91. https://doi.org/10.1186/s12933-020-01066-9
|
[13]
|
Yurista, S.R., Silljé, H.H.W., Oberdorf-Maass, S.U., Schouten, E., Pavez Giani, M.G., Hillebrands, J., et al. (2019) Sodium-glucose Co-Transporter 2 Inhibition with Empagliflozin Improves Cardiac Function in Non-Diabetic Rats with Left Ventricular Dysfunction after Myocardial Infarction. European Journal of Heart Failure, 21, 862-873. https://doi.org/10.1002/ejhf.1473
|
[14]
|
Udell, J.A., Jones, W.S., Petrie, M.C., Harrington, J., Anker, S.D., Bhatt, D.L., et al. (2022) Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week. Journal of the American College of Cardiology, 79, 2058-2068. https://doi.org/10.1016/j.jacc.2022.03.353
|
[15]
|
Corbett, M.S., Higgins, J.P.T. and Woolacott, N.F. (2013) Assessing Baseline Imbalance in Randomised Trials: Implications for the Cochrane Risk of Bias Tool. Research Synthesis Methods, 5, 79-85. https://doi.org/10.1002/jrsm.1090
|
[16]
|
李兆. 达格列净对急性心梗合并2型糖尿病患者PCI术后心室重构的影响研究[D]: [硕士学位论文]. 西安: 西安医学院, 2022.
|
[17]
|
魏方勇, 陈静静, 王伟荣. 达格列净对急性心肌梗死合并2型糖尿病PCI术后患者心功能的影响[J]. 临床合理用药, 2023, 16(7): 19-22.
|
[18]
|
牛广鑫, 王文远. 达格列净对急性心肌梗死患者心功能影响研究[J]. 中文科技期刊数据库(全文版)医药卫生, 2022(8): 4-6.
|
[19]
|
何立兰. 达格列净对急性ST段抬高型心肌梗死急诊PCI患者心室重构及预后的影响[D]: [硕士学位论文]. 张家口: 河北北方学院, 2022.
|
[20]
|
张廷川, 边长勇, 李海涛. 早期应用卡格列净对急性心肌梗死合并2型糖尿病患者经皮冠状动脉介入术后心功能及预后的影响[J]. 中国心血管病研究, 2022, 20(2): 166-170.
|
[21]
|
王法斌, 孙梦涵, 赵强, 等. 早期应用达格列净在急性心肌梗死急诊经皮冠状动脉介入术后患者中的有效性及安全性[J]. 实用医学杂志, 2023, 39(13): 1688-1692.
|
[22]
|
王要鑫, 刘洁云, 秦雷, 等. 达格列净在非糖尿病老年患者急性ST段抬高型心肌梗死PPCI术后的近期疗效观察[J]. 临床心血管病杂志, 2023, 39(2): 126-128.
|
[23]
|
Dayem, K.A., Younis, O., Zarif, B., Attia, S. and AbdelSalam, A. (2023) Impact of Dapagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients—DACAMI (A Randomized Controlled Clinical Trial). International Journal of Cardiology, 379, 9-14. https://doi.org/10.1016/j.ijcard.2023.03.002
|
[24]
|
von Lewinski, D., Kolesnik, E., Tripolt, N.J., Pferschy, P.N., Benedikt, M., Wallner, M., et al. (2022) Empagliflozin in Acute Myocardial Infarction: The EMMY Trial. European Heart Journal, 43, 4421-4432. https://doi.org/10.1093/eurheartj/ehac494
|
[25]
|
Aziri, B., Begic, E., Stanetic, B., Mladenovic, Z. and Kovacevic-Preradovic, T. (2024) Sodium-Glucose Cotransporter-2 Inhibitors: A Swinging Pendulum in the Treatment of Acute Myocardial Infarction. Minerva Cardiology and Angiology, 72, 237-250. https://doi.org/10.23736/s2724-5683.22.06200-7
|
[26]
|
Ferrario, C.M. (2006) Role of Angiotensin II in Cardiovascular Disease—Therapeutic Implications of More than a Century of Research. Journal of the Renin-Angiotensin-Aldosterone System, 7, 3-14. https://doi.org/10.3317/jraas.2006.003
|
[27]
|
Puglisi, S., Rossini, A., Poli, R., Dughera, F., Pia, A., Terzolo, M., et al. (2021) Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. Frontiers in Endocrinology, 12, Article 738848. https://doi.org/10.3389/fendo.2021.738848
|
[28]
|
Lee, T., Chang, N. and Lin, S. (2017) Dapagliflozin, a Selective SGLT2 Inhibitor, Attenuated Cardiac Fibrosis by Regulating the Macrophage Polarization via STAT3 Signaling in Infarcted Rat Hearts. Free Radical Biology and Medicine, 104, 298-310. https://doi.org/10.1016/j.freeradbiomed.2017.01.035
|
[29]
|
Yu, Y., Que, J., Liu, S., Huang, K., Qian, L., Weng, Y., et al. (2022) Sodium-Glucose Co-Transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy. Frontiers in Cardiovascular Medicine, 8, Article 768214. https://doi.org/10.3389/fcvm.2021.768214
|
[30]
|
Paolisso, P., Bergamaschi, L., Santulli, G., Gallinoro, E., Cesaro, A., Gragnano, F., et al. (2022) Infarct Size, Inflammatory Burden, and Admission Hyperglycemia in Diabetic Patients with Acute Myocardial Infarction Treated with SGLT2-Inhibitors: A Multicenter International Registry. Cardiovascular Diabetology, 21, Article No. 77. https://doi.org/10.1186/s12933-022-01506-8
|
[31]
|
陈诚, 张钲, 彭瑜, 等. SGLT2抑制剂在急性心肌梗死中的保护作用[J]. 临床心血管病杂志, 2024, 40(5): 411-415.
|
[32]
|
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., et al. (2014) Glycemic Control with Empagliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorates Cardiovascular Injury and Cognitive Dysfunction in Obese and Type 2 Diabetic Mice. Cardiovascular Diabetology, 13, Article No. 148. https://doi.org/10.1186/s12933-014-0148-1
|
[33]
|
Aroor, A.R., Das, N.A., Carpenter, A.J., Habibi, J., Jia, G., Ramirez-Perez, F.I., et al. (2018) Glycemic Control by the SGLT2 Inhibitor Empagliflozin Decreases Aortic Stiffness, Renal Resistivity Index and Kidney Injury. Cardiovascular Diabetology, 17, Article No. 108. https://doi.org/10.1186/s12933-018-0750-8
|
[34]
|
Mahaffey, K.W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., et al. (2018) Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation, 137, 323-334. https://doi.org/10.1161/circulationaha.117.032038
|
[35]
|
Oyama, K., Raz, I., Cahn, A., Kuder, J., Murphy, S.A., Bhatt, D.L., et al. (2021) Obesity and Effects of Dapagliflozin on Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial. European Heart Journal, 43, 2958-2967. https://doi.org/10.1093/eurheartj/ehab530
|
[36]
|
McGuire, D.K., Zinman, B., Inzucchi, S.E., Wanner, C., Fitchett, D., Anker, S.D., et al. (2020) Effects of Empagliflozin on First and Recurrent Clinical Events in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Secondary Analysis of the EMPA-REG OUTCOME Trial. The Lancet Diabetes & Endocrinology, 8, 949-959. https://doi.org/10.1016/s2213-8587(20)30344-2
|
[37]
|
Zhu, Y., Zhang, J., Yan, X., Sun, L., Ji, Y. and Wang, F. (2022) Effect of Dapagliflozin on the Prognosis of Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Cardiovascular Diabetology, 21, Article No. 186. https://doi.org/10.1186/s12933-022-01627-0
|
[38]
|
Paolisso, P., Bergamaschi, L., Gragnano, F., Gallinoro, E., Cesaro, A., Sardu, C., et al. (2023) Outcomes in Diabetic Patients Treated with SGLT2-Inhibitors with Acute Myocardial Infarction Undergoing PCI: The SGLT2-I AMI PROTECT Registry. Pharmacological Research, 187, Article ID: 106597. https://doi.org/10.1016/j.phrs.2022.106597
|
[39]
|
Wu, Y., Wang, S. and Wang, L. (2022) SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction? American Journal of Cardiovascular Drugs, 22, 601-613. https://doi.org/10.1007/s40256-022-00545-6
|
[40]
|
Mozawa, K., Kubota, Y., Hoshika, Y., Tara, S., Tokita, Y., Yodogawa, K., et al. (2021) Empagliflozin Confers Reno-Protection in Acute Myocardial Infarction and Type 2 Diabetes Mellitus. ESC Heart Failure, 8, 4161-4173. https://doi.org/10.1002/ehf2.13509
|